High-Frequency Oscillation in Early Acute Respiratory Distress Syndrome (OSCILLATE)
AI-Generated Summary
Educational summary — always verify with primary sourceHigh-frequency oscillatory ventilation (HFOV) was widely used in ARDS based on physiological rationale (very small tidal volumes, high mean airway pressure). OSCILLATE was the definitive RCT.
Multicenter RCT (39 ICUs in 5 countries, n=548) comparing HFOV vs. lung-protective conventional ventilation in moderate-to-severe ARDS.
HFOV increased in-hospital mortality (47% vs 35%, RR 1.33, p=0.005). The trial was stopped early for harm. HFOV patients required more sedation, neuromuscular blockade, and vasopressors.
HFOV is HARMFUL in ARDS and should NOT be used. This trial, along with OSCAR (UK), definitively ended routine HFOV use in adult ARDS. Know this for boards — HFOV increases mortality.
High mean airway pressure protocol used in HFOV arm may have caused hemodynamic compromise. Concurrent OSCAR trial also showed no benefit.
Board pearl: HFOV = increased mortality. This is a classic "what NOT to do" trial. Contrast with prone positioning (PROSEVA) which reduces mortality.
Access the complete publication on PubMed